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Abstract 
Generation of bile is a key function of the liver. Its impairment leads to accumulation of 
cytotoxic bile salts in hepatocytes and consequently to liver disease. The bile salt export pump 
Bsep is critically involved in secretion of bile salts into bile. Its function can be disturbed or 
abolished by inherited mutations. This will lead to progressive intrahepatic cholestais and 
severe liver disease. In addition to mutations, Bsep can be inhibited by acquired factors such 
as for example xenobiotics or drugs, aberrant bile salt metabolites or pregnancy. This 
inhibition will lead to acquired cholestasis. Some drugs are now known to be competitive 
inhibitors of Bsep. In addition, a polymorphism in the gene coding for Bsep has been 
identified as a potential susceptibility factor for acquired cholestasis. 
Introduction 
Bile is produced by the liver and delivered to the small intestine, where it is indispensable for 
the absorption of lipids and of fat soluble vitamins. Lipids are an important dietary energy 
source and fat soluble vitamins are vital for many processes, e.g. vitamin K deficiency leads 
to a disturbed balance of the blood clotting system. Hence, ongoing bile formation by the liver 
and undisturbed bile flow is key to vital processes in our body. A major constituent of the bile 
fluid are bile salts. Bile salts are amphipathic molecules and display detergent properties 
(Hofmann, 2009). As such they are toxic to cells, such as for example hepatocytes. An 
additional role of bile is the disposal of lipophilic metabolic end-products, xenobiotics such as 
dietary toxins or drugs and their metabolites. Hence, waste products secreted into bile can 
potentially interfere with processes involved in bile formation. 
 
Bile salts are synthesized from cholesterol in hepatocytes, from where they are secreted into 
the canaliculi. From there they flow via the biliary tree into the gall bladder (except in species, 
which have none) (Hofmann and Hagey, 2008; Hofmann, 2009). From the gall bladder, bile 
salts are released with bile into the duodenum where they promote digestion and absorption of 
fat. Along the small intestine, bile salts are absorbed to more than 90 % both passively and 
actively and transported back to the liver via the portal circulation. In the liver, bile salts are 
taken up into hepatocytes, from where they are secreted again into bile (Alrefai and Gill, 
2007; Pellicoro and Faber, 2007; Hofmann and Hagey, 2008; Kosters and Karpen, 2008; 
Dawson et al., 2009). This circling of bile salts between the liver and the small intestine is 
called enterohepatic circulation. 
 
Bile salt secretion by hepatocytes is maintained by transport systems for uptake located in the 
sinusoidal or basolateral membrane in coordination with export systems located in the 
canalicular or apical membrane of hepatocytes (Meier and Stieger, 2002; Trauner and Boyer, 
2003; Kullak-Ublick et al., 2004; Dawson et al., 2009). Uptake of bile salts across the 
sinusoidal membrane occurs predominantly in a sodium dependent manner and is mediated by 
the sodium-taurocholate cotransporting polypeptide NTCP (SLC10A1) and to minor extent by 
the sodium independent organic anion transporting polypeptides or OATPs (members of the 
SLCOs) (Meier and Stieger, 2002; Alrefai and Gill, 2007; Dawson et al., 2009). In addition, 
OATPs are also mediators of hepatocellular drug and xenobiotic uptake, as exemplified 
recently for bosentan (Treiber et al., 2007). Knowledge on intracellular transport of bile salts 
from the basolateral to the apical plasma membrane is still scarce, but it is assumed that 
binding proteins are involved. Canalicular export occurs against a steep concentration 
gradient and is mediated by a member of the ATP-binding cassette (ABC) transporter family: 
the bile salt export pump BSEP (ABCB11) (Stieger et al., 2007; Dawson et al., 2009; Stieger, 
2009). The rate limiting step in the overall transport from the portal blood into bile is located 
to the canalicular membrane of hepatocytes. Hence, proper functioning of BSEP is essential 
for keeping the potentially cytotoxic bile salts at a low intracellular level in hepatocytes. 
Furthermore, as bile formation is an isoosmotic process, bile salts are a major driving force 
for the generation of canalicular bile flow. A reduction of bile flow represents a 
pathophysiologic situation and is called cholestais. Metabolism of bile salts within 
hepatocytes leads to sulphated  and glucuronidated bile salts, particularly in cholestatic 
conditions, which are excreted into bile via the multidrug resistance protein MRP2 (ABCC2), 
or back into the sinusoids by MRP3 and MRP4, two salvage systems which help to reduce 
potentially cytotoxic intracellular bile salts (Zollner and Trauner, 2006; Geier et al., 2007). In 
addition, the heterodimeric organic solute transporter OSTα-OSTβ is also expressed in the 
basolateral membrane (Ballatori et al., 2009). The relative contribution of these three adaptive 
efflux systems is at the moment not fully understood and needs to be worked out in detail.  
 
The bile salt export pump 
Bsep has been cloned from several species including mouse, rat and human (Stieger et al., 
2007; Stieger, 2009). It is highly specific in all three species for monanionic, conjugated bile 
salts and all isoforms display comparably transport properties. Bsep transports barely any 
uncojugated bile acids (Gerloff et al., 1998), which is supported in vivo by the observation 
that patients with a defect in bile acid conjugation have very little unconjugated bile acids in 
their bile (Carlton et al., 2003). A comparison of rat Bsep and Mrp2 revealed no overlap in 
substrates (Stieger et al., 2000). It should however be noted, that human Bsep is able to 
mediate transport of taurolithocholate-3-sulfate, which is not a substrate for rat Bsep (Hayashi 
et al., 2005). In addition, pravastatin, but not cerivastatin, fluvastatin or pitavastatin, has been 
found to be transported by human and to a lesser extent by rat Bsep. Hence while the substrate 
specificity of Bsep is narrowed in on conjugated bile salts in all species studied, it is not 
identical and Bsep from different species may be able to accept additional different substrates. 
 
As the substrates of Bsep are negative charged, they do not diffuse freely across membranes. 
Therefore, assay systems have to be used, which allow access of the substrate as well as of the 
highly membrane-impermeable ATP to the respective binding sites located at the cytoplasmic 
side of Bsep. One assay system constitutes plasma membrane vesicles, which are for example 
isolated from the cananalicular plasma membrane (Adachi et al., 1991; Muller et al., 1991; 
Nishida et al., 1991; Stieger et al., 1992) or from cells transfected with Bsep. In this system, 
where part of the vesicles are oriented inside-out, not only ATP and the bile salt, but also 
other substances such as potential inhibitors have free access to the cytoplasmic portion of 
Bsep. An alternate system used are sandwich cultured primary hepatocytes, which retain their 
bile salt transport protein polarity and secrete bile salts from the incubation medium into the 
canalicular lumen (Liu et al., 1999). However, if additional substances are to be tested for 
interaction with Bsep, they have to cross the basolateral membrane of hepatocytes first. As a 
consequence, their concentration (as well as of bile salts imported via the basolateral 
membrane) is unknown at the time when they interact with Bsep. Importantly, these two 
systems have the advantage that they represent to a large extent the in vivo situation, in which 
multiple ABC transporters are expressed in the canalicular membrane. If Bsep is to be studied 
isolated from other canalicular transporters, heterologous expression systems are needed. A 
frequently used system is the baculovirus system in conjunction with insect cell lines, from 
which fractions containing Bsep expressing membrane vesicles can be isolated for transport 
studies (Stieger et al., 2000). Alternate expression systems for the production of membrane 
vesicles are HEK293 (Hayashi et al., 2005) or Balb-3T3 cells (Green et al., 2000). Following 
a different approach, polar cell lines, such as for example MCDK cells can be used for 
heterologous expression of hepatocellular transporters (Mita et al., 2005). The sodium-
dependent taurocholate uptake system Ntcp and the exporter Bsep localize to the 
basolaterateral and apical membrane domain of MDCK cells, respectively. MDCK cells can 
be grown in the Transwell® system, which allows experimental access to the basolateral and 
to the apical cell pole of MDCK cells. Hence, hepatocellular bile salt transporters can be 
studied in a transcellular flux set up similar to the hepatocyte sandwich system. In principle, 
the different expression systems as well as the different membrane environments (for example 
insect versus mammalian membranes) lead to comparable results. However, recent evidence 
suggests that the cholesterol content of the membrane positively modulates Bsep activity (Kis 
et al., 2009; Paulusma et al., 2009). In this review, data obtained from ATPase assays with 
Bsep will not be discussed, as so far no detailed molecular characterization of the molecular 
coupling of ATPase activity and of transport activity of has been published for Bsep. 
 
Role of BSEP in liver disease 
In humans, BSEP is essential in export of bile salts from hepatocytes into the canaliculus. 
This is evidenced by the fact the patients with inherited mutations in the ABCB11 gene 
resulting in the absence of functional BSEP in the canalicular membrane develop early in life 
severe liver disease and are at a high risk to develop liver malignancies (Strautnieks et al., 
1998; Knisely et al., 2006). Patients with mutations in the ABCB11 gene display progressive 
intrahepatic familial cholestasis type 2 (PFIC2) and have extremely low levels bile salts in 
their bile, which is indicative of a lack of canalicular bile salt secretion (Jansen et al., 1999). 
In these patients, bile salts as well as other toxic cholephilic substances accumulate within 
hepatocytes and ultimately lead to hepatocyte necrosis. The lack of bile salts in the bile of 
these patients leads to alterations in intestinal lipid and fat soluble vitamin absorption, the 
latter putting them at risk for impairment of blood clotting. Not all mutations in the ABCB11 
gene lead to a severe clinical phenotype, but also to milder forms such as benign recurrent 
intrahepatic cholestais type 2 (BRIC2). Hence, mutations in the ABCB11 gene lead to a 
continuum from mild to progressive and severe forms of cholestatic liver disease altogether 
resulting in BSEP deficiency syndrome (Pauli-Magnus et al., 2005). 
 
To date, several dozen mutations in the ABCB11 gene are known. These mutations include 
missense mutations, nonsense mutations, deletions and insertions as well as splice site 
mutations. Recently, an exhaustive study with 109 families of patients with severe BSEP 
deficiency syndrome not only reported on the mutations in the ABCB11 gene, but also studied 
the expression of BSEP with immunohistochemistry in a large number of patient biopsies 
(Strautnieks et al., 2008). Of note, the majority of patients had absent BSEP staining 
indicating no protein expression as a consequence of the mutations. A second group of 
patients presented with abnormal BSEP staining ranging from reduced BSEP expression to 
mistargeted BSEP in hepatocytes. Some mutations, e.g. E297G are found in patients with 
severe as well as with benign BSEP deficiency syndrome (Pauli-Magnus et al., 2005). 
Functional characterization of the E297G variant of BSEP revealed residual transport activity 
(Noe et al., 2005). The fact that mutations in the ABCB11 also lead to a benign recurrent form 
of cholestatsis raises the question on the minimal amount of functional BSEP secreting bile 
salts, which is needed in the canaliculus for normal liver function. This question will be 
difficult to answer, as access to human liver tissue, in particular from healthy livers, is very 
limited and information on bile salt secretion from patients is usually not available. A 
comparison of BSEP expression levels (among other canalicular ABC-transporters) in 110 
healthy liver tissue samples demonstrated a considerable variation of BSEP expression levels 
in normal human liver tissue (Meier et al., 2006). 
 
Role of BSEP in acquired cholestasis 
The observation that some mutations of BSEP having residual transport activity lead to mild 
forms of BSEP deficiency syndrome provides a pathophysiological basis for the concept that 
inhibition of BSEP by drugs or xenobiotics can lead to acquired intrahepatic cholestasis. For 
example, in a patient with benign recurrent intrahepatic cholestasis type 2, the two compound 
heterozygous mutations E297G and R432T were identified. BSEP staining in a liver biopsy 
revealed normal canalicular staining. However, individual in vitro kinetic characterization of 
the two mutant BSEP forms demonstrated a massively reduced vmax value of the two forms 
with no relevant change in the Km value for taurocholate (Noe et al., 2005). Hence, the 
overall capacity for canalicular secretion of bile salts is massively reduced in this patient. It 
can be speculated that in symptom-free intervals, this residual transport capacity is sufficient 
to allow a seemingly normal liver function, which in the cholestatic episodes is probably 
further impaired by other yet unknown factors. In addition, Bsep can be inhibited by 
endogenous metabolites, such as for example aberrant bile salts, which occur in patients with 
inborn errors in the biosynthesis of bile salts inhibit Bsep (Stieger et al., 1997). If untreated, 
this disease also manifests with progressive cholestasis (Sundaram et al., 2008). 
 
While inherited severe BSEP deficiency syndromes are very rare, drug induced liver injury 
including cholestasis is a relevant clinical issue leading to many hospital admissions ending in 
severe cases with liver transplantation (Bleibel et al., 2007). In addition, drug induced liver 
injury is an important factor leading attrition of drugs during development or to withdrawal of 
drugs from the market (Schuster et al., 2005; Smith and Schmid, 2006). Hence, drug induced 
liver injury poses a significant burden to the costs of modern health care systems. 
Unfortunately, the underlying pathogenetic mechanism(s) of drug induced liver injury often 
remain(s) enigmatic (hence the term idiosyncratic liver injury). After the cloning of rat Bsep 
as the first bile salt export pump, it could be demonstrated that some drugs are able to inhibit 
Bsep and hence can cause drug-induced cholestasis (Stieger et al., 2000). Cyclosporin, 
rifamycin SV, rifampicin and glibenclamide are competitive inhibitors of rat Bsep with 
comparable Ki values as determined in rat canalicular plasma membrane vesicles (table 1). 
Extending these studies to human BSEP later demonstrated that cyclosporin A, rifampicin and 
glibenclamide all inhibit human BSEP in a competitive manner (table 1). The clinical 
relevance of this concept was first demonstrated with bosentan. Bosentan is a dual endothelin 
receptor antagonist, whereby bosentan and one of its main metabolites are pharmacologically 
active. They are taken up by OATP1B1 and OATP1B3 into hepatocytes and mainly 
eliminated via bile (Treiber et al., 2007). During clinical trials, bosentan was observed to 
cause asymptomatic, reversible transaminase elevations in some patients (Fattinger et al., 
2001). The incidence of liver injury was dose dependent as plasma bile salt levels in affected 
individuals increased with increasing dose of bosentan. Furthermore, individuals, which in 
addition to bosentan were taking glyburide, showed a higher incidence of liver injury than 
patients who were on bosentan alone. Studies with rat Bsep expressed in Sf9 cell vesicles 
subsequently demonstrated that bosentan and one of its metabolites are competitive Bsep 
inhibitors (table 1). Also, bosentan treatment of rats lead, as in humans; to an elevation of 
plasma bile salt levels, which was more pronounced if glibenclamide was coadministered 
(Fattinger et al., 2001). After cloning of human BSEP, bosentan turned out to be a competitive 
inhibitor of BSEP, too (table 1). Therefore, the fact that the serum bile salt levels positively 
correlated with the bosentan dose as well as the spontaneous normalization of serum liver 
parameters after stopping of bosentan strongly suggest that also in vivo in human liver 
bosentan acts as a competitive BSEP inhibitor. This effect could be rather specific on BSEP, 
as no elevation of serum bilirubin was observed (Fattinger et al., 2001). The list of 
Bsep/BSEP inhibitors is continuosly growing and examples are given in table 1. 
 
Troglitazone is an example of a drug, which was withdrawn from the market due to its 
hepatotoxicity. The exact mechanisms of its toxic action remain somewhat enigmatic, but a 
consensus has emerged that that troglitazone are toxic to mitochondria (Masubuchi, 2006; 
Julie et al., 2008). In addition, troglitazone administration in rats leads to an acute reduction to 
bile flow and hence is cholestatic (Preininger et al., 1999). Troglitazone-sulphate is the main 
metabolite of troglitazone in rats and excreted into bile (Funk et al., 2001). Both, the parent 
compound and its sulphated metabolite are competitive inhibitors of rat canalicular plasma 
membrane vesicles (table 1). Recently, troglitazone was also found to be an inhibitor of dog 
and human BSEP (table 1). Hence, troglitazone can negatively impact mitochondria directly 
as well as by inhibiting BSEP followed by an accumulation of bile salts in hepatocytes. Bile 
salts by themselves are toxic to mitochondria (Krahenbuhl et al., 1994). Drug induced liver 
injury often results not only in cholestatic but in mixed (hepatocellular and cholestatic) liver 
injury (Meier et al., 2005). Using as additional thiazolidinediones, both rosiglitazone and 
ciglitazone inhibit taurocholate transport into rat canalicular plasma membrane vesicles, 
suggesting a class effect on Bsep inhibition (Snow and Moseley, 2007). This clearly 
demonstrates that the toxicity of troglitazone requires additional mechanisms to its cholestatic 
potential. 
 
Cholestasis of pregnancy is a rare complication of pregnancies and shows marked regional 
differences in incidence (Zollner and Trauner, 2006). This is an indication that genetic factors 
are important in rendering patients susceptible to this form of cholestasis. Furthermore, 
metabolites of estrogen and/or progesterone are implicated in its pathogenesis. Hence, 
intrahepatic cholestasis of pregnancy is also an acquired form of cholestasis. Estrogen 
metabolites are also involved in cholestasis induced by oral contraceptives. In animal 
experiments, estradiol-17β-glucuronide has been demonstrated to be strongly cholestatic 
(Huang et al., 2000). Its cholestatic action is dependent on the expression of Mrp2 in the 
canaliculus. Interestingly and surprisingly, estradiol-17β-glucuronide did not inhibit 
taurocholate transport in Sf9 cell vesicles expressing Bsep (Stieger et al., 2000). However, if 
in the same vesicles Bsep and Mrp2 were coexpressed, estradiol-17β-glucuronide inhibits 
Bsep mediated taurocholate transport activity in a time- and dose-dependent manner. This is 
in line with the observation in rats that Mrp2 is strictly required for the cholestatic potential of 
estradiol-17β-glucuronide. Hence, Bsep can also be indirectly inhibited and it was postulated 
that estradiol-17β-glucuronide inhibits Bsep by trans-inhibition, i.e. it needs to be secreted 
into the canalicular lumen to exert its inhibitory and consequently cholestatic property. This 
result was later confirmed and extended to sulphated progesteron metabolites (Akita et al., 
2001; Vallejo et al., 2005). The same inhibitory principle is also described for the epidermal 
growth factor receptor inhibitor PKI166 (Takada et al., 2004). 
 
Most interestingly, in an extension of the investigation of the cholestatic potential of bosentan 
in rats it was found that bosentan leads to a stimulation of bile flow and not – as expected – to 
a reduction of bile flow (Fouassier et al., 2002). While bile flow was increased, bile salt 
output remained unchanged with a consequently lower bile salt concentration in bile. The 
stimulation of the bile flow was again dependent on the presence of functional Mrp2 in the 
canaliculus. Hence, bosentan presents an additional example of the involvement of Mrp2 in 
the cholestatic effect of a substance. A study using rat and human Mrp2/MRP2 as well as 
Bsep/BSEP expressed in Sf9 cells confirmed the inhibition by bosentan of both isoforms of 
Bsep/BSEP (Mano et al., 2007). Moreover it demonstrated that the transport activity of 
Mrp2/MRP2 was stimulated by bosentan, which explains the observed increase of bile salt 
independent bile flow in rats. Taken together, Bsep can either be inhibited directly by drug 
form the cytoplasm or indirectly, most probably from the canalicular side. This process seems 
to need the presence of Mrp2. 
 
Susceptibility to Acquired Cholestasis 
Drug induced cholestasis a relevant and often severe clinical issue. However, the risk for such 
an event is rare (Russmann et al., 2005). One such risk factor could for example be the 
existence of variants of the ABCB11 gene as a consequence of single nucleotide 
polymorphisms. Several studies reporting on frequencies of polymorphismsms in the ABCB11 
gene have been published. Until now, the non-synonomous c.1331T>C (p.V444A) in exon 13 
and c.2029A>G (p.M677V) in exon 17 have consistently been reported to have frequencies of 
higher than 0.5 % (Saito et al., 2002; Pauli-Magnus et al., 2004; Lang et al., 2006). 
Investigation of the expression of four canalicular ABC transporters including BSEP in 110 
healthy liver samples revealed that the p.V444A variant tended to lower BSEP expression 
levels (Meier et al., 2006). Kinetic characterization of the two BSEP isoforms in the Sf9 cell 
expression system demonstrated indiscernible transport properties of the V444 and the A444 
BSEP variant (Lang et al., 2007). Hence, individuals carrying the p.V444A variant could be 
more prone to acquired cholestais. This hypothesis is supported by the observation that in 
patients with drug induced cholestasis as well as in patients with cholestasis of pregnancy the 
frequency of c.1331T>C is significantly higher than in controls (Lang et al., 2007; Meier et al., 
2008; Dixon et al., 2009). These three studies therefore suggest that the c.1331T>C 
(p.V444A) variant of ABCB11 could be a susceptibility factor for acquired cholestasis. In 
addition and in further support of these results, three case reports describing two patients with 
cholestasis of pregnancy and one patient with benign recurrent intrahepatic cholestasis type 2 
identified homocygosity for 1331T in one and heterozygosity for this variant in two patients 
(Keitel et al., 2006; Kubitz et al., 2006; Muehlenberg et al., 2008). An extensive in vitro 
characterization of the impact of mutations and single-nucleotide polymorphisms in the 
ABCB11 gene found that the 1331T variant leads to lower expression levels of BSEP in CHO 
cells (Byrne et al., 2009). Hence this finding represents additional support for the hypothesis 
that the 1331T variant of the ABCB11 gene could be a susceptibility factor for acquired 
cholestasis and confirms the findings from the study on BSEP protein expression in healthy 
human liver tissue. Clearly, larger prospective studies in independent cohorts are now needed 
to confirm this finding, in particular as a study in a Swedish cohort of women with 
intrahepatic cholestasis of pregnancy found no difference in the distribution of common BSEP 
haplotypes (Wasmuth et al., 2007). It is important to note that the latter study compared 
haplotypes, while the other studies investigated frequencies of single nucleotide 
polymorphisms. 
 
Conclusion 
In conclusion, impairment of the function of BSEP either by inherited mutations or by single 
nucleotide polymorphisms as well as by inhibition of its transport activity can lead to 
cholestasis, which in some patients develops into severe liver disease. Kinetic characterization 
of rodent and human BSEP as well as studies on the inhibition of rodent and human Bsep 
have shown that these isoforms have comparable kinetic properties. However, for several 
reasons, this approach should be used cautiously: First, the substrate specificity of rat and 
human Bsep is similar, but not identical (Stieger et al., 2000; Hayashi et al., 2005). Second, 
kinetic parameters both for substrates and inhibitors are comparable, but not identical (table 1). 
Hence, extrapolation from preclinical rodent data to the human in vivo situation may be 
difficult. However, if an inhibition of Bsep in rodent systems is observed either in vitro or in 
vivo, this clearly rises a flag for human studies and warrants in such studies to closely follow 
serum bile salt levels. Third mice with an ablated Abcb11 gene do not present with severe 
cholestasis on a normal diet (Wang et al., 2001). Only if these mice are put on high cholate 
diet, they will develop severe cholestasis, which leads to rapid death of male, but not female 
mice (Wang et al., 2003). Mice with absent Bsep secrete novel tetrahydroxylated bile salts 
into their bile (Wang et al., 2001), which highlights the important interplay of bile salt 
metabolism and transport to protect hepatocytes from bile salt toxicity. Furthermore, these 
mice present with highly upregulated p-glycoprotein, which in vitro can transport bile salts 
and hence could potentially act as a salvage system (Lam et al., 2005). 
While it is well established now that inhibition of BSEP by drugs and other xenobiotics can 
lead to cholestasis, a better understanding of the factors rendering individuals susceptible to 
such outcomes is clearly needed. This will require both, prospective clinical studies in 
conjunction with genome wide analysis, such as it was recently reported for statin-induced 
myopathy (Link et al., 2008) as well as further investigation on molecular aspects of Bsep, 
keeping both, direct and indirect inhibition of BSEP in mind. And finally, with the growing 
list of known Bsep inhibitors, it seems feasible that quantitative structure-activity relationship 
analysis will lead to a better understanding of the chemical properties of Bsep inhibitors 
(Hirano et al., 2006). 
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Table 1 
inhibitor test system Ki or IC50 reference 
bosentan 
 
bosentan M2 
rat Bsep in Sf9 cells 
BSEP in Sf9 cells 
rat Bsep in Sf9 cells 
Ki 12 µM 
Ki 37 µM 
Ki 8.5 µM 
(Fattinger et al., 2001) 
(Noe et al., 2002) 
(Fattinger et al., 2001) 
chlorpromazine rat canalicular vesicles Ki 506 µM (Horikawa et al., 2003) 
cloxacillin rat canalicular vesicles 
human canalicular vesicles 
Ki 74.8 µM 
yes 
(Horikawa et al., 2003) 
(Horikawa et al., 2003) 
colchicine rat canalicular vesicles Ki 539 µM (Horikawa et al., 2003) 
cyclosporine rat canalicular vesicles 
 
 
human canalicular vesicles 
Ki 0.2 µM 
Ki 1.1 
IC50 0.8 µM 
yes 
(Bohme et al., 1994) 
(Horikawa et al., 2003) 
(Funk et al., 2001) 
(Horikawa et al., 2003) 
cyclosporine human hepatocyte 
sandwich system 
concentration 
dependent 
(Kostrubsky et al., 2003) 
CI-1034 human hepatocyte 
sandwich system, 
concentration 
dependent 
(Kostrubsky et al., 2003) 
ciglitazone rat canalicular vesicles concentration 
dependent 
(Snow and Moseley, 2007) 
cyclosporine rat Bsep in Sf9 cells 
BSEP in high five cells 
Ki 0.3 µM 
Ki 9.5 µM 
(Stieger et al., 2000) 
(Byrne et al., 2002) 
doxycycline rat canalicular vesicles Ki 530 µM (Horikawa et al., 2003) 
erythromycin 
estolate 
human hepatocyte 
sandwich system 
concentration 
dependent 
(Kostrubsky et al., 2003) 
fendiline BSEP in Sf9 celsl yes (Hirano et al., 2006) 
fusidate rat canalicular vesicles Ki 2.2 µM (Bode et al., 2002) 
 
glibenclamide rat canalicular vesicles 
 
 
human canalicular vesicles 
Ki 5.7 µM 
Ki 5.3 µM 
IC50 8.6 µM 
yes 
(Stieger et al., 2000) 
(Horikawa et al., 2003) 
(Funk et al., 2001) 
(Horikawa et al., 2003) 
glibenclamide rat Bsep in Sf9 cells 
BSEP in high five cells 
Ki 6.1 µM 
Ki 27.5 µM 
(Stieger et al., 2000) 
(Byrne et al., 2002) 
glibenclamide human hepatocyte 
sandwich system 
concentration 
dependent 
(Kostrubsky et al., 2003) 
lovastatin not specified yes (Funk, 2008) 
mideamycin rat canalicular vesicles 
human canalicular vesicles 
Ki 154 µM 
yes 
(Horikawa et al., 2003) 
(Horikawa et al., 2003) 
    
nefazodone human hepatocyte 
sandwich system 
IC50 14 µM (Kostrubsky et al., 2006) 
nefadozone BSEP in Sf9 cells IC50 9 µM (Kostrubsky et al., 2006) 
nicardipine BSEP in Sf9 cells yes (Hirano et al., 2006) 
nifedipine BSEP in Sf9 cells yes (Hirano et al., 2006) 
PKI166 rat canalicular vesicles yes (Takada et al., 2004) 
pravastatin BSEP in Sf9 cells IC50 240 µM (Yabuuchi et al., 2008) 
prenylamine BSEP in Sf9 cells yes (Hirano et al., 2006) 
quinidine rat canalicuaar vesicles Ki 542 µM (Horikawa et al., 2003) 
rifampicin rat canalicular vesicles Ki 6.4 µM (Stieger et al., 2000) 
rifampicin rat Bsep in Sf9 cells 
BSEP in high five cells 
Ki 11.9 µM 
Ki 31 µM 
(Stieger et al., 2000) 
(Byrne et al., 2002) 
rifamycin SV rat canalicular vesicles Ki 0.9 µM (Stieger et al., 2000) 
rifamycin SV rat Bsep in Sf9 cells Ki 3.8 µM (Stieger et al., 2000) 
ritonavir BSEP ind Sf9 cells yes (McRae et al., 2006) 
rosiglitazone rat canalicular vesicels concentration 
dependent 
(Snow and Moseley, 2007) 
saquinavir BSEP in Sf9 cells yes (McRae et al., 2006) 
troglitazone rat canalicular vesicles Ki 1.3 µM 
concentration 
dependent 
(Funk et al., 2001) 
(Snow and Moseley, 2007) 
troglitazone rat hepatocyte sandwich 
system 
human hepatocyte 
sandwich system 
concentration 
dependent 
concentration 
dependent 
(Marion et al., 2007) 
 
(Marion et al., 2007) 
troglitazone sulfate rat canalicuar vesicles Ki 0.23 µM (Funk et al., 2001) 
troleandomycin human hepatocyte concentration (Kostrubsky et al., 2003) 
sandwich system dependent 
verapamil rat canalicular vesicles Ki 93 µM (Horikawa et al., 2003) 
 
Table 1: Examples of drugs which have been demonstrated to inhibit Bsep. 
